BioLife Solutions, Inc.
HealthcareNASDAQ:BLFS · NASDAQ Capital Market
-$0.50 today
Vol 0.69M · Avg 0.51M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $0 +100.0% | -$20.2M +69.6% | -$66.4M +52.5% | -$139.8M -1731.1% | -$7.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $0 -100.0% | $5.5M -55.3% | $12.3M -25.4% | $16.5M +28.0% | $12.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 +100.0% | -$64.0K -3.2% | -$62.0K +98.8% | -$5.2M +74.0% | -$20.1M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $30.9M -2.4% | $31.7M +25.0% | $25.3M +81.5% | $14.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$8.9M -4024.7% | $227.0K -84.5% | $1.5M +109.8% | -$14.9M -560.1% | -$2.3M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $264.0K +109.1% | -$2.9M -118.9% | $15.4M +242.8% | -$10.8M -6.1% | -$10.1M | $592.6M | $1.3B | $626.2M |
| Inventory | -$1.3M -262.4% | $781.0K +109.1% | -$8.6M -30.4% | -$6.6M -5853.5% | $114.0K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$2.1M -8123.1% | $26.0K +100.3% | -$8.4M -2135.0% | $414.0K -79.5% | $2.0M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$5.8M -350.9% | $2.3M -25.0% | $3.1M +55.2% | $2.0M -65.3% | $5.7M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $29.0M +464.5% | -$8.0M -193.0% | $8.6M -92.2% | $109.7M +6798.4% | -$1.6M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $20.1M +138.6% | $8.4M +167.5% | -$12.5M -47.2% | -$8.5M -75.5% | -$4.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$9.5M -193.7% | -$3.2M +49.4% | -$6.4M +38.6% | -$10.4M -23.9% | -$8.4M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 -100.0% | $60.4M | $0 | $0 -100.0% | $1.6M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 +100.0% | -$18.4M +32.0% | -$27.1M +49.0% | -$53.1M -733.7% | -$6.4M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 -100.0% | $21.9M -61.0% | $56.2M +529.7% | $8.9M +40.0% | $6.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$71.5M -2921.1% | -$2.4M +51.2% | -$4.9M -37.3% | -$3.5M +39.2% | -$5.8M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$71.5M -222.7% | $58.3M +226.8% | $17.8M +130.7% | -$58.1M -359.7% | -$12.6M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$10.0M -51.3% | -$6.6M -1226.9% | -$498.0K -102.8% | $17.8M +716.3% | -$2.9M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $18.0K -91.1% | $202.0K -98.0% | $10.2M +5235.4% | $192.0K -84.9% | $1.3M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$942.0K -149.9% | -$377.0K -144.6% | $845.0K +149.4% | -$1.7M -47.9% | -$1.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$10.9M -61.0% | -$6.8M -164.0% | $10.6M -35.1% | $16.3M +687.4% | -$2.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 -100.0% | $35.0K +132.4% | -$108.0K +61.7% | -$282.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$62.3M -204.0% | $59.9M +275.5% | $16.0M +131.7% | -$50.4M -144.8% | -$20.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $10.6M +104.4% | $5.2M +127.6% | -$18.9M -0.0% | -$18.9M -42.8% | -$13.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.42B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
AtriCure, Inc.
NASDAQ:ATRC
$1.46B
STAAR Surgical Company
NASDAQ:STAA
$1.41B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Phreesia, Inc.
NYSE:PHR
$560.02M
SEC Filings
Recent regulatory filings
No filings found.
Does BLFS generate free cash flow?
BioLife Solutions, Inc. (BLFS) generated $10.64M of free cash flow in fiscal 2025.
How much operating cash flow does BLFS produce?
Operating cash flow was $20.11M, before capital expenditures of $9.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.